CVS Group plc (LON:CVSG)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 816.62M |
| Revenue (ttm) | 692.80M |
| Net Income (ttm) | 49.40M |
| Shares Out | 70.16M |
| EPS (ttm) | 0.69 |
| PE Ratio | 50.83 |
| Forward PE | 12.83 |
| Dividend | 0.09 (0.73%) |
| Ex-Dividend Date | Nov 6, 2025 |
| Volume | 30,444 |
| Average Volume | 322,123 |
| Open | 1,200.00 |
| Previous Close | 1,164.00 |
| Day's Range | 1,166.00 - 1,200.00 |
| 52-Week Range | 994.00 - 1,648.00 |
| Beta | 1.07 |
| RSI | 41.35 |
| Earnings Date | Sep 24, 2026 |
About CVS Group
CVS Group plc, together with its subsidiaries, engages in veterinary, online pharmacy, and retail businesses in the United Kingdom and Australia. It operates through the Veterinary Practices, Laboratories, and Online Retail Business segments. The company is involved in animal veterinary practices and complementary veterinary diagnostic businesses. It also operates Animed Direct, an online retail business that sells prescription and non-prescription medicines, pet foods, and other pet care products, as well as an online dispensary. In addition, ... [Read more]
Financial Performance
In fiscal year 2025, CVS Group's revenue was 673.20 million, an increase of 5.40% compared to the previous year's 638.70 million. Earnings were 52.80 million, an increase of 751.61%.
Financial StatementsNews
UK's CVS Group CEO to step down after 7 years at the helm
British veterinary services provider CVS Group said on Monday CEO Richard Fairman plans to retire after seven years in the role.
Half Year 2026 CVS Group PLC Earnings Presentation Transcript
Half Year 2026 CVS Group PLC Earnings Presentation Transcript
CVS Group PLC (FRA:4C9) (H1 2026) Earnings Call Highlights: Strong Revenue Growth Amid Market ...
CVS Group PLC (FRA:4C9) (H1 2026) Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges
Half Year 2026 CVS Group PLC Earnings Call Transcript
Half Year 2026 CVS Group PLC Earnings Call Transcript
CVS Group PLC (FRA:4C9) Half Year 2026 Earnings Call Highlights: Strategic Expansion and ...
CVS Group PLC (FRA:4C9) Half Year 2026 Earnings Call Highlights: Strategic Expansion and Resilience Amidst Economic Challenges
Half Year 2026 CVS Group PLC Earnings Call-Q&A Transcript
Half Year 2026 CVS Group PLC Earnings Call-Q&A Transcript
CVS Group Earnings Call Transcript: H1 2026
Revenue and EBITDA grew despite inflation and weak UK consumer confidence, with strong margin performance in Australia and successful rebranding and regulatory compliance initiatives. UK and Australia acquisition pipelines remain robust, supporting a positive outlook.
CVS Group Earnings Call Transcript: H1 2026
Revenue grew 5.8% year-over-year to GBP 356.9 million, with adjusted EBITDA up 3.9% and strong cash flow supporting continued investment. Australia now contributes 10% of revenue and 15% of EBITDA, while the group maintains leverage well below its target ceiling.
UK's CVS Group plans Main Market move, approves near $27 million buyback
Veterinary services provider CVS Group said on Friday it plans to move its listing from the Alternative Investment Market to the London Stock Exchange's Main Market, while also approving a new 20 mill...
CVS Group Transcript: Investor Update
Revenue rose 5.4% to £673.2m and adjusted EBITDA grew 9.4%, with strong cash generation and leverage reduced to 1.18x. Expansion in Australia continues, UK acquisitions are set to resume post-CMA, and medium-term like-for-like growth guidance is 4–8%.
CVS Group Earnings Call Transcript: H2 2025
Revenue grew 5.4% to £673.2m, with adjusted EBITDA up 9.4% and margin at 20%. Australian expansion continued, and UK operations improved, with strong cash flow and reduced leverage. Confident in medium-term 4%-8% growth, supported by efficiency gains and selective acquisitions.
CVS Group Earnings Call Transcript: H2 2025
Revenue grew 5.4% to GBP 673.2 million, with Adjusted EBITDA up 9.4% and margin at 20%. Strong cash flow, reduced leverage, and continued expansion in Australia position the group for further growth, despite ongoing CMA investigation and sector headwinds.
CVS Group Earnings Call Transcript: H1 2025
Revenue rose 6.6% to £341.8m and EBITDA grew 4.5% to £67.4m, with strong expansion in Australia and ongoing UK regulatory uncertainty. The business remains confident in its five-year EBITDA doubling plan and targets a 23% margin by 2027, supported by operational synergies and disciplined capital allocation.
Intel faces possible split, CVS group president: Market Domination
There's just one more hour to go in Tuesday's trading day, Julie Hyman and Alexandra Canal are here to cover the day's biggest market stories and speak to Wall Street experts on today's Market Dominat...
CVS Group Earnings Call Transcript: H2 2024
Revenue grew 9.9% to £647.3m, with adjusted EBITDA up 4.7% to £127.3m, driven by UK and Australian acquisitions. Despite headwinds from a cyber incident and CMA scrutiny, confidence remains in meeting full-year expectations and margin targets.